|

HLX10 Clinical Trials

4 actively recruiting trials

▼ -2 trials since June 2026

Also known as: Serplulimab, serplulimab

Pipeline

Phase 2: 2Phase 3: 1Phase 2/3: 1

Top Sponsors

  • Shanghai Henlius Biotech2
  • Tianjin Medical University Cancer Institute and Hospital1
  • Tao Zhang1

Indications

  • Cancer4
  • Resectable Esophageal Squamous Cell Carcinoma1
  • Liver Disease1
  • Total Neoadjuvant Therapy1
  • Rectal Cancer1

Other4 trials

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Phase 2/3
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
Phase 3
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Phase 2
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.